Scholarlink

<p>Despite advances in understanding the mechanisms, risk factors and treatment strategies for Alzheimer’s disease (AD), no approved therapies exist to prevent or delay onset in at-risk individuals or those with elevated biomarkers who do not yet show symptoms. Multiple candidate interventions are now being evaluated in clinical trials in these settings, raising key questions around which populations are most appropriate and what criteria should guide regulatory and clinical decision-making. Data are expected within 1–2 years, underscoring the need for stakeholder alignment on clinically meaningful and acceptable characteristics of preventative therapies or other products. To address this need, the Global CEO Initiative on Alzheimer’s Disease convened an international group of experts to develop target product profiles for therapies designed to delay or prevent the onset of clinical symptoms in AD. These target product profiles outline minimum and preferred characteristics, including intended use, target populations, safety expectations and efficacy benchmarks. This effort provides a foundational framework to accelerate therapeutic development and guide researchers, regulators and patients in the evaluation of emerging therapies for preventing symptomatic AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Target product profiles for treatments to delay or prevent symptomatic Alzheimer’s disease

  • 期刊论文

  • 发表日期：

    2026年4月3日

查看全文
  • Jeffrey L. Cummings,
  • Michael G. Agadjanyan,
  • Maureen Barry,
  • Lawrence Corey,
  • Rachelle Doody,
  • Suzanne Hendrix,
  • Soeren Mattke,
  • Niklas Mattsson-Carlgren,
  • Eric McDade,
  • Joseph P. Menetski,
  • Richard C. Mohs,
  • Katherine A. Partrick,
  • Nikolai Petrovsky,
  • Dennis J. Selkoe,
  • Diego Silva,
  • Reisa A. Sperling,
  • Benjamin Tiede,
  • George Vradenburg

摘要

Despite advances in understanding the mechanisms, risk factors and treatment strategies for Alzheimer’s disease (AD), no approved therapies exist to prevent or delay onset in at-risk individuals or those with elevated biomarkers who do not yet show symptoms. Multiple candidate interventions are now being evaluated in clinical trials in these settings, raising key questions around which populations are most appropriate and what criteria should guide regulatory and clinical decision-making. Data are expected within 1–2 years, underscoring the need for stakeholder alignment on clinically meaningful and acceptable characteristics of preventative therapies or other products. To address this need, the Global CEO Initiative on Alzheimer’s Disease convened an international group of experts to develop target product profiles for therapies designed to delay or prevent the onset of clinical symptoms in AD. These target product profiles outline minimum and preferred characteristics, including intended use, target populations, safety expectations and efficacy benchmarks. This effort provides a foundational framework to accelerate therapeutic development and guide researchers, regulators and patients in the evaluation of emerging therapies for preventing symptomatic AD.